Neurology:不同亚型卒中复发风险高而各异,复发死亡风险进一步增加!

2021-12-04 Naomi MedSci原创

 近日,有研究人员根据对预后有重要意义的不同患者特征,分别检查了卒中亚型和卒中复发的10年风险。两种亚型中风复发的风险都很大,但不同亚型患者的风险明显不同。复发中风死亡风险高于首次中风。

      与首次卒中相比,尽管有复发风险的卒中幸存者的数量正在增加,但很少关注复发卒中的流行病学。2011年的一项荟萃分析汇集了13项研究和9115名首次卒中幸存者的数据,发现卒中发作后1年的复发风险为11%,5年的复发风险为26%,10年的复发风险为39%。一项来自南伦敦卒中登记和Erlanger的卒中项目,发现了较低的预估风险(1年为5-8%,5年为13-20%)。重要的是,这些研究没有考虑到相互竞争的死亡风险,导致潜在的高估风险,纳入患者通常较少(<4,000名患者),患者的风险估计不准确,并且没有使用统一的复发定义。此外,根据卒中亚型代表潜在干预目标的患者亚组之间的复发风险证据甚微。

      人们普遍认为复发性卒中比首次发作更具有致命性和致残性,但目前缺乏针对复发性卒中死亡率的大规模人群研究。近日,有研究人员根据对预后有重要意义的不同患者特征,分别检查了卒中亚型和卒中复发的10年风险,还检查了首次卒中和复发卒中后的全因死亡率和卒中特异性死亡率。

      使用丹麦全国健康登记,研究纳入了2004年至2018年首次缺血性卒中(N=105,397)或脑出血(N=13,350)的患者(年龄≥18岁)。考虑到相互竞争的死亡风险,分别计算了每个卒中亚型和年龄、性别、卒中严重程度、体重指数、吸烟、酗酒、Essen卒卒中险评分和心房颤动的卒中复发的绝对风险。计算首次卒中和复发卒中后的死亡风险。

  • 在调整了相互竞争的风险后,总的1年和10年复发风险在首次缺血性卒中后分别为4%和13%,在首次脑出血后分别为3%和12%。
  • 对于缺血性卒中,复发的风险随着年龄的增长而增加,男性的复发风险更高,轻度卒中比重度卒中的复发风险更高。
  • 最显著的差异是不同的埃森风险评分,其复发风险随着评分的增加而增加。
  • 对于脑出血,男女的风险是相似的,并且不会随着Essen风险评分的增加而增加。
  • 对于缺血性卒中,首次卒中后1年和10年全因死亡的风险分别为17%和56%,复发卒中后为25%和70%;脑出血的相应估计值在首次事件后为37%和70%,在复发事件后为31%和75%。

 两种亚型卒中复发的风险都很大,但不同亚型患者的风险明显不同。卒中复发后的死亡风险高于首次卒中。

文献来源:Skajaa N, Adelborg K, Horváth-Puhó E, et al. Risks of Stroke Recurrence and Mortality After First and Recurrent Strokes in Denmark: A Nationwide Registry Study [published online ahead of print, 2021 Nov 29]. Neurology. 2021;10.1212/WNL.0000000000013118. doi:10.1212/WNL.0000000000013118

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1905594, encodeId=3c391905594af, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Jun 20 03:18:12 CST 2022, time=2022-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001628, encodeId=eca62001628d4, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Apr 15 07:18:12 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184512, encodeId=c003118451286, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4d75638647, createdName=YHW, createdTime=Sat Jan 15 09:27:40 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077570, encodeId=648710e757003, content=新观点, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eb45553384, createdName=小松松, createdTime=Mon Dec 06 23:58:43 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077499, encodeId=503a10e74992b, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/P1zD45U2k0CKbiaAUJS5pQNBiamic8emic8DeoNiaV1cj697m0icc4BWmKicYuykyia7ictxBLs6tLgFLQN1pKBSrNoquAw/132, createdBy=a2352353251, createdName=shooter9599, createdTime=Mon Dec 06 21:02:17 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256151, encodeId=55c11256151e1, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Dec 05 05:18:12 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391634, encodeId=d3d01391634a5, content=<a href='/topic/show?id=f8ab3603664' target=_blank style='color:#2F92EE;'>#卒中复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36036, encryptionId=f8ab3603664, topicName=卒中复发)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLc3PoqaNe4QTZ947pojXuchvvmkkJN0wyBBbA3LVX2WDkgiaJ7cswu9yvA4CB0NicjcrCfBY1zRPkA/132, createdBy=b3812500089, createdName=ms6897892027066920, createdTime=Sun Dec 05 05:18:12 CST 2021, time=2021-12-05, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1905594, encodeId=3c391905594af, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Jun 20 03:18:12 CST 2022, time=2022-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001628, encodeId=eca62001628d4, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Apr 15 07:18:12 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184512, encodeId=c003118451286, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4d75638647, createdName=YHW, createdTime=Sat Jan 15 09:27:40 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077570, encodeId=648710e757003, content=新观点, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eb45553384, createdName=小松松, createdTime=Mon Dec 06 23:58:43 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077499, encodeId=503a10e74992b, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/P1zD45U2k0CKbiaAUJS5pQNBiamic8emic8DeoNiaV1cj697m0icc4BWmKicYuykyia7ictxBLs6tLgFLQN1pKBSrNoquAw/132, createdBy=a2352353251, createdName=shooter9599, createdTime=Mon Dec 06 21:02:17 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256151, encodeId=55c11256151e1, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Dec 05 05:18:12 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391634, encodeId=d3d01391634a5, content=<a href='/topic/show?id=f8ab3603664' target=_blank style='color:#2F92EE;'>#卒中复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36036, encryptionId=f8ab3603664, topicName=卒中复发)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLc3PoqaNe4QTZ947pojXuchvvmkkJN0wyBBbA3LVX2WDkgiaJ7cswu9yvA4CB0NicjcrCfBY1zRPkA/132, createdBy=b3812500089, createdName=ms6897892027066920, createdTime=Sun Dec 05 05:18:12 CST 2021, time=2021-12-05, status=1, ipAttribution=)]
    2022-04-15 yinhl1978
  3. [GetPortalCommentsPageByObjectIdResponse(id=1905594, encodeId=3c391905594af, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Jun 20 03:18:12 CST 2022, time=2022-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001628, encodeId=eca62001628d4, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Apr 15 07:18:12 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184512, encodeId=c003118451286, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4d75638647, createdName=YHW, createdTime=Sat Jan 15 09:27:40 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077570, encodeId=648710e757003, content=新观点, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eb45553384, createdName=小松松, createdTime=Mon Dec 06 23:58:43 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077499, encodeId=503a10e74992b, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/P1zD45U2k0CKbiaAUJS5pQNBiamic8emic8DeoNiaV1cj697m0icc4BWmKicYuykyia7ictxBLs6tLgFLQN1pKBSrNoquAw/132, createdBy=a2352353251, createdName=shooter9599, createdTime=Mon Dec 06 21:02:17 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256151, encodeId=55c11256151e1, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Dec 05 05:18:12 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391634, encodeId=d3d01391634a5, content=<a href='/topic/show?id=f8ab3603664' target=_blank style='color:#2F92EE;'>#卒中复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36036, encryptionId=f8ab3603664, topicName=卒中复发)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLc3PoqaNe4QTZ947pojXuchvvmkkJN0wyBBbA3LVX2WDkgiaJ7cswu9yvA4CB0NicjcrCfBY1zRPkA/132, createdBy=b3812500089, createdName=ms6897892027066920, createdTime=Sun Dec 05 05:18:12 CST 2021, time=2021-12-05, status=1, ipAttribution=)]
    2022-01-15 YHW

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1905594, encodeId=3c391905594af, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Jun 20 03:18:12 CST 2022, time=2022-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001628, encodeId=eca62001628d4, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Apr 15 07:18:12 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184512, encodeId=c003118451286, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4d75638647, createdName=YHW, createdTime=Sat Jan 15 09:27:40 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077570, encodeId=648710e757003, content=新观点, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eb45553384, createdName=小松松, createdTime=Mon Dec 06 23:58:43 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077499, encodeId=503a10e74992b, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/P1zD45U2k0CKbiaAUJS5pQNBiamic8emic8DeoNiaV1cj697m0icc4BWmKicYuykyia7ictxBLs6tLgFLQN1pKBSrNoquAw/132, createdBy=a2352353251, createdName=shooter9599, createdTime=Mon Dec 06 21:02:17 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256151, encodeId=55c11256151e1, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Dec 05 05:18:12 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391634, encodeId=d3d01391634a5, content=<a href='/topic/show?id=f8ab3603664' target=_blank style='color:#2F92EE;'>#卒中复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36036, encryptionId=f8ab3603664, topicName=卒中复发)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLc3PoqaNe4QTZ947pojXuchvvmkkJN0wyBBbA3LVX2WDkgiaJ7cswu9yvA4CB0NicjcrCfBY1zRPkA/132, createdBy=b3812500089, createdName=ms6897892027066920, createdTime=Sun Dec 05 05:18:12 CST 2021, time=2021-12-05, status=1, ipAttribution=)]
    2021-12-06 小松松

    新观点

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1905594, encodeId=3c391905594af, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Jun 20 03:18:12 CST 2022, time=2022-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001628, encodeId=eca62001628d4, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Apr 15 07:18:12 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184512, encodeId=c003118451286, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4d75638647, createdName=YHW, createdTime=Sat Jan 15 09:27:40 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077570, encodeId=648710e757003, content=新观点, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eb45553384, createdName=小松松, createdTime=Mon Dec 06 23:58:43 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077499, encodeId=503a10e74992b, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/P1zD45U2k0CKbiaAUJS5pQNBiamic8emic8DeoNiaV1cj697m0icc4BWmKicYuykyia7ictxBLs6tLgFLQN1pKBSrNoquAw/132, createdBy=a2352353251, createdName=shooter9599, createdTime=Mon Dec 06 21:02:17 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256151, encodeId=55c11256151e1, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Dec 05 05:18:12 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391634, encodeId=d3d01391634a5, content=<a href='/topic/show?id=f8ab3603664' target=_blank style='color:#2F92EE;'>#卒中复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36036, encryptionId=f8ab3603664, topicName=卒中复发)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLc3PoqaNe4QTZ947pojXuchvvmkkJN0wyBBbA3LVX2WDkgiaJ7cswu9yvA4CB0NicjcrCfBY1zRPkA/132, createdBy=b3812500089, createdName=ms6897892027066920, createdTime=Sun Dec 05 05:18:12 CST 2021, time=2021-12-05, status=1, ipAttribution=)]
    2021-12-06 shooter9599

    学习了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1905594, encodeId=3c391905594af, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Jun 20 03:18:12 CST 2022, time=2022-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001628, encodeId=eca62001628d4, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Apr 15 07:18:12 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184512, encodeId=c003118451286, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4d75638647, createdName=YHW, createdTime=Sat Jan 15 09:27:40 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077570, encodeId=648710e757003, content=新观点, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eb45553384, createdName=小松松, createdTime=Mon Dec 06 23:58:43 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077499, encodeId=503a10e74992b, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/P1zD45U2k0CKbiaAUJS5pQNBiamic8emic8DeoNiaV1cj697m0icc4BWmKicYuykyia7ictxBLs6tLgFLQN1pKBSrNoquAw/132, createdBy=a2352353251, createdName=shooter9599, createdTime=Mon Dec 06 21:02:17 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256151, encodeId=55c11256151e1, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Dec 05 05:18:12 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391634, encodeId=d3d01391634a5, content=<a href='/topic/show?id=f8ab3603664' target=_blank style='color:#2F92EE;'>#卒中复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36036, encryptionId=f8ab3603664, topicName=卒中复发)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLc3PoqaNe4QTZ947pojXuchvvmkkJN0wyBBbA3LVX2WDkgiaJ7cswu9yvA4CB0NicjcrCfBY1zRPkA/132, createdBy=b3812500089, createdName=ms6897892027066920, createdTime=Sun Dec 05 05:18:12 CST 2021, time=2021-12-05, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1905594, encodeId=3c391905594af, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Jun 20 03:18:12 CST 2022, time=2022-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001628, encodeId=eca62001628d4, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Apr 15 07:18:12 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184512, encodeId=c003118451286, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4d75638647, createdName=YHW, createdTime=Sat Jan 15 09:27:40 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077570, encodeId=648710e757003, content=新观点, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eb45553384, createdName=小松松, createdTime=Mon Dec 06 23:58:43 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077499, encodeId=503a10e74992b, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/P1zD45U2k0CKbiaAUJS5pQNBiamic8emic8DeoNiaV1cj697m0icc4BWmKicYuykyia7ictxBLs6tLgFLQN1pKBSrNoquAw/132, createdBy=a2352353251, createdName=shooter9599, createdTime=Mon Dec 06 21:02:17 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256151, encodeId=55c11256151e1, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Dec 05 05:18:12 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391634, encodeId=d3d01391634a5, content=<a href='/topic/show?id=f8ab3603664' target=_blank style='color:#2F92EE;'>#卒中复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36036, encryptionId=f8ab3603664, topicName=卒中复发)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLc3PoqaNe4QTZ947pojXuchvvmkkJN0wyBBbA3LVX2WDkgiaJ7cswu9yvA4CB0NicjcrCfBY1zRPkA/132, createdBy=b3812500089, createdName=ms6897892027066920, createdTime=Sun Dec 05 05:18:12 CST 2021, time=2021-12-05, status=1, ipAttribution=)]

相关资讯

2019 ACOG委员会意见:遗传性癌症综合征和风险评估(No.793)

2019年12月,美国妇产科医师学会(ACOG)发布了遗传性癌症综合征和风险评估的第793号委员会意见。遗传性癌症综合征是某些类型癌症的遗传易感性,通常在早期发病,是由一个或多个基因的遗传致病性突变引起,本文主要针对遗传性癌症综合征的风险评估提供指导建议。

Nat Med:多基因和临床风险评分及其对心脏代谢疾病和常见癌症发病年龄的影响和预测

多基因风险评分(PRSs)在预测常见疾病的易感性中表现出了良好的前景。

Br J Cancer:乳腺导管原位癌保乳手术后结合放疗的长期风险评估

自1990年代引入基于人群的乳房X光进行乳腺癌筛查以来,乳腺导管原位癌(DCIS)约占所有新确诊的乳腺癌的15%。

Alzheimer Dementia :中年时控制血压可降低痴呆风险

中年时控制血压可降低痴呆风险

Prostate Cancer P D:临床病理模型在高风险局部前列腺癌中的表现

在已经建立的临床病理风险组中,前列腺癌表现出了生物学和临床的遗传异质性。Decipher genomic classifier(GC)是一个已经验证过的方法,用于进一步对前列腺癌患者进行风险分层,但是

CLIN CHEM LAB MED:基于质量指标和Sigma指标的整个测试过程的风险评估

对实验室表现进行基于证据的评估,包括整个检测过程(TTP)的分析前、分析和分析后阶段,对于确保患者获得安全、高效和有效的护理至关重要。为了进行风险评估,不断使用质量管理工具,如失效模式和效果分析(FM

拓展阅读

Neurology:Chance-2试验1年随访——替格瑞洛与氯吡格雷治疗卒中或短暂性脑缺血发作 CYP2C19功能丧失携带者的一年疗效比较 

对于 CYP2C19功能丧失等位基因携带者,早期替格瑞洛双重抗血小板治疗在减少复发性卒中方面优于氯吡格雷。

Neurology:全省分流系统对短暂性脑缺血发作的影响: ASPIRE 干预 

在有组织的卒中系统的背景下,ASPIRE TIA分类和管理干预不能进一步减少卒中复发。干预后明显较低的死亡率可能与被确定为TIA的事件后监测的改善有关,但不能排除长期趋势。

Stroke:隐匿性脑梗死是心房颤动患者卒中复发的危险因素

该研究的结果表明,房颤合并CBI可能增加卒中复发的风险。可考虑采用隐性脑梗死来估计房颤患者的卒中风险。

Neurology:未经证实的颈动脉血运重建获益患者斑块炎症与卒中复发的关联

近日,研究人员证实SCAIL 评分提高了在动脉内膜切除术试验中未获益的亚组中早期复发性卒中的识别。目前,还需要进行随机试验来测试联合狭窄-炎症策略是否会改善目前不确定益处的颈动脉血运重建的选择。

Stroke:急性卒中后的长期生存率、卒中复发和预期寿命

在这个人群范围的研究中,急性卒中后的死亡和复发很常见,并且急性卒中与预期寿命的大幅减少有关。为了降低这些风险,需要进一步改进卒中的治疗和二级预防。

Stroke:脂蛋白(a)对卒中复发的影响

在缺血性卒中/短暂性脑缺血发作患者中,Lp(a)水平升高与卒中复发风险显著相关。然而,在低LDL-Cc或IL-6水平下,Lp(a)相关的卒中复发风险在二级预防中有所降低。